GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Selling, General, & Admin. Expense

RSLS (Reshape Lifesciences) Selling, General, & Admin. Expense : $9.19 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Reshape Lifesciences's selling, general, & admin. expense for the three months ended in Mar. 2025 was $2.16 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2025 was $9.19 Mil.


Reshape Lifesciences Selling, General, & Admin. Expense Historical Data

The historical data trend for Reshape Lifesciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Selling, General, & Admin. Expense Chart

Reshape Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.22 33.21 31.34 17.87 9.92

Reshape Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.89 2.79 2.80 1.44 2.16

Competitive Comparison of Reshape Lifesciences's Selling, General, & Admin. Expense

For the Medical Devices subindustry, Reshape Lifesciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Selling, General, & Admin. Expense Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Selling, General, & Admin. Expense falls into.


;
;

Reshape Lifesciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (NAS:RSLS) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Reshape Lifesciences Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
18 Technology Drive, Suite 110, Irvine, CA, USA, 92618
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022